BERNS PAUL L — SEC Form 4 filings
SEC reporting owner CIK 1202769. 15 Form 4 filings on record with FilingPulse; latest filed 2026-08-21.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-02-16 to 2026-08-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 2,528,088 shares, $46,719,949 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 23,690 shares, $57,927 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 39.
- Largest priced transaction: purchase of 1,250,000 shares @ $16.00 ($20,000,000) in Kardigan, Inc., filed 2026-06-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Kardigan, Inc. (KARD) | Director, 10% owner | 2 | 1 leg · 1,250,000 sh · $20,000,000 | — | 5 |
| Metsera, Inc. (MTSR) | Director | 3 | 1 leg · 789,998 sh · $14,219,964 | — | 11 |
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 1 | 1 leg · 488,090 sh · $12,499,985 | — | — |
| Neumora Therapeutics, Inc. (NMRA) | See Remarks, Director | 8 | — | 2 legs · 23,690 sh · $57,927 | 22 |
| Unity Biotechnology, Inc. (UBX) | Director | 1 | — | — | 1 |
Form 4 filings — BERNS PAUL L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Kardigan, Inc. (KARD) | Purchase (P): 1,250,000 @ $16 | EDGAR |
| 2026-06-22 | 4 | Kardigan, Inc. (KARD) | Conversion (C): 13,792,035 · Grant/award (A): 20,706 @ $0 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative) | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN, BYBEE CLINTON | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2026-02-19 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 9,819 @ $3.51 | EDGAR |
| 2026-01-09 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 1,650,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Metsera, Inc. (MTSR) | Disposition to issuer (D): 4,031 · Disposition to issuer (D): 7,523,682 · Disposition to issuer (D): 8,313,680 · Disposition to issuer (D): 957,559 · Grant/award (A): 4,031 (derivative) · Disposition to issuer (D): 24,188 (derivative) · +1 more | EDGAR |
| 2025-05-30 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 497,049 (derivative) · Disposition to issuer (D): 955,864 (derivative) · Disposition to issuer (D): 342,500 (derivative) · Disposition to issuer (D): 2,000,000 (derivative) · Grant/award (A): 497,049 (derivative) · Grant/award (A): 955,864 (derivative) · +2 more | EDGAR |
| 2025-05-22 | 4 | Metsera, Inc. (MTSR) | Grant/award (A): 24,188 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 13,871 @ $1.69 | EDGAR |
| 2025-02-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 2,000,000 (derivative) @ $0 · Disposition to issuer (D): 497,049 (derivative) · Disposition to issuer (D): 955,864 (derivative) · Disposition to issuer (D): 342,500 (derivative) · Grant/award (A): 497,049 (derivative) · Grant/award (A): 955,864 (derivative) · +1 more | EDGAR |
| 2025-02-03 | 4 | Metsera, Inc. (MTSR) | Conversion (C): 7,523,682 · Purchase (P): 789,998 @ $18 · Conversion (C): 15,000,000 (derivative) · Conversion (C): 2,678,571 (derivative) | EDGAR |
| 2024-12-27 | 4 | Neumora Therapeutics, Inc. (NMRA) | Gift (G): 133,097 @ $0 · Gift (G): 133,097 @ $0 · Gift (G): 133,097 @ $0 | EDGAR |
| 2024-06-21 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 171,250 @ $0 · Grant/award (A): 342,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1202769 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →